Analyzing Phathom Pharmaceuticals (NASDAQ:PHAT) and INmune Bio (NASDAQ:INMB)

Phathom Pharmaceuticals (NASDAQ:PHAT) and INmune Bio (NASDAQ:INMB) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, profitability, valuation, dividends and risk.

Earnings and Valuation

This table compares Phathom Pharmaceuticals and INmune Bio”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Phathom Pharmaceuticals	$175.11 million	4.61	-$221.25 million	($2.12)	-4.78
INmune Bio	$50,000.00	669.82	-$45.93 million	($1.67)	-0.75

INmune Bio has lower revenue, but higher earnings than Phathom Pharmaceuticals. Phathom Pharmaceuticals is trading at a lower price-to-earnings ratio than INmune Bio, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Phathom Pharmaceuticals and INmune Bio, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Phathom Pharmaceuticals	1	0	5	1	2.86
INmune Bio	2	2	1	1	2.17

Phathom Pharmaceuticals currently has a consensus target price of $24.50, indicating a potential upside of 141.86%. INmune Bio has a consensus target price of $8.00, indicating a potential upside of 534.92%. Given INmune Bio’s higher probable upside, analysts plainly believe INmune Bio is more favorable than Phathom Pharmaceuticals.

Volatility & Risk

Phathom Pharmaceuticals has a beta of 0.51, suggesting that its share price is 49% less volatile than the S&P 500. Comparatively, INmune Bio has a beta of 1.03, suggesting that its share price is 3% more volatile than the S&P 500.

Profitability

This table compares Phathom Pharmaceuticals and INmune Bio’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Phathom Pharmaceuticals	-76.77%	N/A	-44.29%
INmune Bio	N/A	-103.03%	-77.66%

Insider and Institutional Ownership

99.0% of Phathom Pharmaceuticals shares are held by institutional investors. Comparatively, 12.7% of INmune Bio shares are held by institutional investors. 9.3% of Phathom Pharmaceuticals shares are held by company insiders. Comparatively, 21.4% of INmune Bio shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

INmune Bio beats Phathom Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

About Phathom Pharmaceuticals

Phathom Pharmaceuticals, Inc., biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.

About INmune Bio

INmune Bio, Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, a mucinous polyglucan on the surface of some epithelial cancer cells that appears to predict resistant to immunotherapy, including women with MUC4 expressing HER2+ breast cancer and other MUC4 resistant cancers. It also provides XPro1595 for the treatment of Alzheimer's disease and treatment resistant depression. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; and University of Pittsburg. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.